The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Open accessAbstract
Interpretation of clinical trials comparing different drug regimens for Parkinson's disease (PD) is complicated by the different dose intensities used: higher doses of levodopa and, possibly, other drugs produce better symptomatic control but more late complications. To address this problem, conversion factors have been calculated for antiparkinsonian drugs that yield a total daily levodopa equivalent dose (LED). LED estimates vary, so we undertook a systematic review of studies reporting LEDs to provide standardized formulae. Electronic database and hand searching of references identified 56 primary reports of LED estimates. Data were extracted and the mean and modal LEDs calculated. This yielded a standardized LED for each drug, providing a useful tool to express dose intensity of different antiparkinsonian drug regimens on a single scale. Using these conversion formulae to report LEDs would improve the consistency of reporting and assist the interpretation of clinical trials comparing different PD medications. © 2010 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease
Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., Daniels, C., Deutschländer, A., Dillmann, U., Eisner, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060281 · Cited by 2,944
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Weaver, F. M. (2009) · JAMA · doi:10.1001/jama.2008.929 · Cited by 1,525
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa000827 · Cited by 1,514
Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
Fenelon, G. (2000) · Brain · doi:10.1093/brain/123.4.733 · Cited by 1,037
Evolution of cognitive dysfunction in an incident Parkinson's disease cohort
Williams-Gray, C. H., Foltynie, T., Brayne, C. E. G., Robbins, T. W., & Barker, R. A. (2007) · Brain · doi:10.1093/brain/awm111 · Cited by 934
Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease
Krack, P. (1998) · Brain · doi:10.1093/brain/121.3.451 · Cited by 608
Effect of GPi pallidotomy on motor function in Parkinson's disease
Lozano, A. M., Lang, A. E., Galvez-Jimenez, N., Miyasaki, J., Duff, J., Hutchison, W. D., & Dostrovsky, J. O. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92404-3 · Cited by 603
Baron, M. S., Vitek, J. L., Green, J., Kaneoke, Y., Hashimoto, T., Turner, R. S., Woodard, J. L., Delong, M. R., Bakay, R. A. E., Cole, S. A., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410400305 · Cited by 558
Hobson, D. E., Lang, A. E., Martin, W. R. W., Razmy, A., Rivest, J., & Fleming, J. (2002) · JAMA · doi:10.1001/jama.287.4.455 · Cited by 553
Cited by
Neurostimulation for Parkinson's Disease with Early Motor Complications
Schuepbach, W. M. M., Rau, J., Knudsen, K., Volkmann, J., Krack, P., Timmermann, L., Hälbig, T. D., Hesekamp, H., Navarro, S. M., Meier, N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205158 · Cited by 1,430
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
van Kessel, S. P., Frye, A. K., El-Gendy, A. O., Castejon, M., Keshavarzian, A., van Dijk, G., & El Aidy, S. (2019) · Nature Communications · doi:10.1038/s41467-019-08294-y · Cited by 521
Sex differences in Parkinson’s disease
Gillies, G. E., Pienaar, I. S., Vohra, S., & Qamhawi, Z. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.02.002 · Cited by 489
Alteration of the fecal microbiota in Chinese patients with Parkinson’s disease
Qian, Y., Yang, X., Xu, S., Wu, C., Song, Y., Qin, N., Chen, S.-D., & Xiao, Q. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.02.016 · Cited by 409
PD MED Collaborative Group (2014) · The Lancet · doi:10.1016/s0140-6736(14)60683-8 · Cited by 407
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism
Barichella, M., Severgnini, M., Cilia, R., Cassani, E., Bolliri, C., Caronni, S., Ferri, V., Cancello, R., Ceccarani, C., Faierman, S., et al. (2019) · Movement Disorders · doi:10.1002/mds.27581 · Cited by 393
Levodopa Is a Double‐Edged Sword for Balance and Gait in People With Parkinson's Disease
Curtze, C., Nutt, J. G., Carlson‐Kuhta, P., Mancini, M., & Horak, F. B. (2015) · Movement Disorders · doi:10.1002/mds.26269 · Cited by 404
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals
Jost, S. T., Kaldenbach, M., Antonini, A., Martinez‐Martin, P., Timmermann, L., Odin, P., Katzenschlager, R., Borgohain, R., Fasano, A., Stocchi, F., et al. (2023) · Movement Disorders · doi:10.1002/mds.29410 · Cited by 389
α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease
Lindestam Arlehamn, C. S., Dhanwani, R., Pham, J., Kuan, R., Frazier, A., Rezende Dutra, J., Phillips, E., Mallal, S., Roederer, M., Marder, K. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15626-w · Cited by 386
Martin-Bastida, A., Ward, R. J., Newbould, R., Piccini, P., Sharp, D., Kabba, C., Patel, M. C., Spino, M., Connelly, J., Tricta, F., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01402-2 · Cited by 379
Gilron, R., Little, S., Perrone, R., Wilt, R., de Hemptinne, C., Yaroshinsky, M. S., Racine, C. A., Wang, S. S., Ostrem, J. L., Larson, P. S., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00897-5 · Cited by 343
Abnormal intrinsic brain functional network dynamics in Parkinson’s disease
Kim, J., Criaud, M., Cho, S. S., Díez-Cirarda, M., Mihaescu, A., Coakeley, S., Ghadery, C., Valli, M., Jacobs, M. F., Houle, S., et al. (2017) · Brain · doi:10.1093/brain/awx233 · Cited by 369
Nanostructured Lipid Carriers (NLCs) for Drug Delivery and Targeting
Fang, C.-L., A. Al-Suwayeh, S., & Fang, J.-Y. (2013) · Recent Patents on Nanotechnology · doi:10.2174/187221013804484827 · Cited by 367
Del Din, S., Godfrey, A., & Rochester, L. (2016) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2015.2419317 · Cited by 363
Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression
Aho, V. T. E., Pereira, P. A. B., Voutilainen, S., Paulin, L., Pekkonen, E., Auvinen, P., & Scheperjans, F. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.05.064 · Cited by 361
Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale
Martínez-Martín, P., Rodríguez-Blázquez, C., Alvarez, M., Arakaki, T., Arillo, V. C., Chaná, P., Fernández, W., Garretto, N., Martínez-Castrillo, J. C., Rodríguez-Violante, M., et al. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.10.026 · Cited by 360
Th17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson's disease
Sommer, A., Marxreiter, F., Krach, F., Fadler, T., Grosch, J., Maroni, M., Graef, D., Eberhardt, E., Riemenschneider, M. J., Yeo, G. W., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.06.015 · Cited by 332
Trial of Lixisenatide in Early Parkinson’s Disease
Meissner, W. G., Remy, P., Giordana, C., Maltête, D., Derkinderen, P., Houéto, J.-L., Anheim, M., Benatru, I., Boraud, T., Brefel-Courbon, C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312323 · Cited by 369
Schwiertz, A., Spiegel, J., Dillmann, U., Grundmann, D., Bürmann, J., Faßbender, K., Schäfer, K.-H., & Unger, M. M. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.02.022 · Cited by 318
Del Din, S., Godfrey, A., Galna, B., Lord, S., & Rochester, L. (2016) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/s12984-016-0154-5 · Cited by 349
The role of small intestinal bacterial overgrowth in Parkinson's disease
Fasano, A., Bove, F., Gabrielli, M., Petracca, M., Zocco, M. A., Ragazzoni, E., Barbaro, F., Piano, C., Fortuna, S., Tortora, A., et al. (2013) · Movement Disorders · doi:10.1002/mds.25522 · Cited by 344
Katzenschlager, R., Poewe, W., Rascol, O., Trenkwalder, C., Deuschl, G., Chaudhuri, K. R., Henriksen, T., van Laar, T., Spivey, K., Vel, S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30239-4 · Cited by 340
Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide
Schade, S., Mollenhauer, B., & Trenkwalder, C. (2020) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12921 · Cited by 338
Prognosis and neuropathologic correlation of clinical subtypes of Parkinson disease
De Pablo-Fernández, E., Lees, A. J., Holton, J. L., & Warner, T. T. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4377 · Cited by 332
A two‐year randomized controlled trial of progressive resistance exercise for Parkinson's disease
Corcos, D. M., Robichaud, J. A., David, F. J., Leurgans, S. E., Vaillancourt, D. E., Poon, C., Rafferty, M. R., Kohrt, W. M., & Comella, C. L. (2013) · Movement Disorders · doi:10.1002/mds.25380 · Cited by 328
Cognitive impairment and resting-state network connectivity in Parkinson's disease
Baggio, H.-C., Segura, B., Sala-Llonch, R., Marti, M.-J., Valldeoriola, F., Compta, Y., Tolosa, E., & Junqué, C. (2015) · Human Brain Mapping · doi:10.1002/hbm.22622 · Cited by 320
Prevalence, Determinants, and Effect on Quality of Life of Freezing of Gait in Parkinson Disease
Perez-Lloret, S., Negre-Pages, L., Damier, P., Delval, A., Derkinderen, P., Destée, A., Meissner, W. G., Schelosky, L., Tison, F., & Rascol, O. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.753 · Cited by 317
Reward Pays the Cost of Noise Reduction in Motor and Cognitive Control
Manohar, S. G., Chong, T. T.-J., Apps, M. A. J., Batla, A., Stamelou, M., Jarman, P. R., Bhatia, K. P., & Husain, M. (2015) · Current Biology · doi:10.1016/j.cub.2015.05.038 · Cited by 317
Propagative α-synuclein seeds as serum biomarkers for synucleinopathies
Okuzumi, A., Hatano, T., Matsumoto, G., Nojiri, S., Ueno, S.-I., Imamichi-Tatano, Y., Kimura, H., Kakuta, S., Kondo, A., Fukuhara, T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02358-9 · Cited by 313
Henderson, E. J., Lord, S. R., Brodie, M. A., Gaunt, D. M., Lawrence, A. D., Close, J. C. T., Whone, A. L., & Ben-Shlomo, Y. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00389-0 · Cited by 304
Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE‐PD)
Williams‐Gray, C. H., Wijeyekoon, R., Yarnall, A. J., Lawson, R. A., Breen, D. P., Evans, J. R., Cummins, G. A., Duncan, G. W., Khoo, T. K., Burn, D. J., et al. (2016) · Movement Disorders · doi:10.1002/mds.26563 · Cited by 304
Dynamic functional connectivity changes associated with dementia in Parkinson’s disease
Fiorenzato, E., Strafella, A. P., Kim, J., Schifano, R., Weis, L., Antonini, A., & Biundo, R. (2019) · Brain · doi:10.1093/brain/awz192 · Cited by 304
Dopamine enhances willingness to exert effort for reward in Parkinson's disease
Chong, T. T.-J., Bonnelle, V., Manohar, S., Veromann, K.-R., Muhammed, K., Tofaris, G. K., Hu, M., & Husain, M. (2015) · Cortex · doi:10.1016/j.cortex.2015.04.003 · Cited by 276
Boutet, A., Madhavan, R., Elias, G. J. B., Joel, S. E., Gramer, R., Ranjan, M., Paramanandam, V., Xu, D., Germann, J., Loh, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23311-9 · Cited by 301
Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson’s Disease
Martínez-Fernández, R., Máñez-Miró, J. U., Rodríguez-Rojas, R., del Álamo, M., Shah, B. B., Hernández-Fernández, F., Pineda-Pardo, J. A., Monje, M. H. G., Fernández-Rodríguez, B., Sperling, S. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2016311 · Cited by 282
Identification of novel biomarkers for Parkinson's disease by metabolomic technologies
Hatano, T., Saiki, S., Okuzumi, A., Mohney, R. P., & Hattori, N. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309676 · Cited by 282
Kustrimovic, N., Comi, C., Magistrelli, L., Rasini, E., Legnaro, M., Bombelli, R., Aleksic, I., Blandini, F., Minafra, B., Riboldazzi, G., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1248-8 · Cited by 278
King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation
Chaudhuri, K. R., Rizos, A., Trenkwalder, C., Rascol, O., Pal, S., Martino, D., Carroll, C., Paviour, D., Falup‐Pecurariu, C., Kessel, B., et al. (2015) · Movement Disorders · doi:10.1002/mds.26270 · Cited by 270
Blood–brain barrier leakage is increased in parkinson’s disease
Al-Bachari, S., Naish, J. H., Parker, G. J. M., Emsley, H. C. A., & Parkes, L. M. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.593026 · Cited by 263
The Parkinson Anxiety Scale (PAS): Development and validation of a new anxiety scale
Leentjens, A. F. G., Dujardin, K., Pontone, G. M., Starkstein, S. E., Weintraub, D., & Martinez‐Martin, P. (2014) · Movement Disorders · doi:10.1002/mds.25919 · Cited by 270
Mak, E., Su, L., Williams, G. B., Firbank, M. J., Lawson, R. A., Yarnall, A. J., Duncan, G. W., Owen, A. M., Khoo, T. K., Brooks, D. J., et al. (2015) · Brain · doi:10.1093/brain/awv211 · Cited by 260
Perera, G., Ranola, M., Rowe, D. B., Halliday, G. M., & Dzamko, N. (2016) · Scientific Reports · doi:10.1038/srep31391 · Cited by 259
Garcia-Ruiz, P. J., Martinez Castrillo, J. C., Alonso-Canovas, A., Herranz Barcenas, A., Vela, L., Sanchez Alonso, P., Mata, M., Olmedilla Gonzalez, N., & Mahillo Fernandez, I. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306787 · Cited by 256
Longitudinal analysis of impulse control disorders in Parkinson disease
Corvol, J.-C., Artaud, F., Cormier-Dequaire, F., Rascol, O., Durif, F., Derkinderen, P., Marques, A.-R., Bourdain, F., Brandel, J.-P., Pico, F., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005816 · Cited by 253
Longitudinal study of normal cognition in Parkinson disease
Pigott, K., Rick, J., Xie, S. X., Hurtig, H., Chen-Plotkin, A., Duda, J. E., Morley, J. F., Chahine, L. M., Dahodwala, N., Akhtar, R. S., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002001 · Cited by 251
Lindqvist, D., Kaufman, E., Brundin, L., Hall, S., Surova, Y., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047387 · Cited by 236
Minor hallucinations occur in drug‐naive Parkinson's disease patients, even from the premotor phase
Pagonabarraga, J., Martinez‐Horta, S., Fernández de Bobadilla, R., Pérez, J., Ribosa‐Nogué, R., Marín, J., Pascual‐Sedano, B., García, C., Gironell, A., & Kulisevsky, J. (2016) · Movement Disorders · doi:10.1002/mds.26432 · Cited by 236
Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting
Uc, E. Y., Doerschug, K. C., Magnotta, V., Dawson, J. D., Thomsen, T. R., Kline, J. N., Rizzo, M., Newman, S. R., Mehta, S., Grabowski, T. J., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000644 · Cited by 230
Speech treatment in Parkinson's disease: Randomized controlled trial (RCT)
Ramig, L., Halpern, A., Spielman, J., Fox, C., & Freeman, K. (2018) · Movement Disorders · doi:10.1002/mds.27460 · Cited by 225
Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial
Schenkman, M., Hall, D. A., Barón, A. E., Schwartz, R. S., Mettler, P., & Kohrt, W. M. (2012) · Physical Therapy · doi:10.2522/ptj.20110472 · Cited by 224
Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease
Martinez-Martin, P., Rodriguez-Blazquez, C., Forjaz, M. J., Frades-Payo, B., Agüera-Ortiz, L., Weintraub, D., Riesco, A., Kurtis, M. M., & Chaudhuri, K. R. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.03.024 · Cited by 222
Kieburtz, K., Tilley, B. C., Elm, J. J., Babcock, D., Hauser, R., Ross, G. W., Augustine, A. H., Augustine, E. U., Aminoff, M. J., Bodis-Wollner, I. G., et al. (2015) · JAMA · doi:10.1001/jama.2015.120 · Cited by 207
Conradsson, D., Löfgren, N., Nero, H., Hagströmer, M., Ståhle, A., Lökk, J., & Franzén, E. (2015) · Neurorehabilitation and neural repair · doi:10.1177/1545968314567150 · Cited by 205
Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers
Okai, D., Askey-Jones, S., Samuel, M., O’Sullivan, S. S., Chaudhuri, K. R., Martin, A., Mack, J., Brown, R. G., & David, A. S. (2013) · Neurology · doi:10.1212/wnl.0b013e3182840678 · Cited by 202
Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease
Müller, T. (2015) · Drugs · doi:10.1007/s40265-014-0343-0 · Cited by 190
Vijiaratnam, N., Girges, C., Auld, G., McComish, R., King, A., Skene, S. S., Hibbert, S., Wong, A., Melander, S., Gibson, R., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02808-3 · Cited by 181
Christine, C. W., Bankiewicz, K. S., Van Laar, A. D., Richardson, R. M., Ravina, B., Kells, A. P., Boot, B., Martin, A. J., Nutt, J., Thompson, M. E., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25450 · Cited by 167
Hertel, J., Harms, A. C., Heinken, A., Baldini, F., Thinnes, C. C., Glaab, E., Vasco, D. A., Pietzner, M., Stewart, I. D., Wareham, N. J., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.035 · Cited by 162
Case Control Polysomnographic Studies of Sleep Disorders in Parkinson's Disease
Yong, M.-H., Fook-Chong, S., Pavanni, R., Lim, L.-L., & Tan, E.-K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022511 · Cited by 152
Probiotics may have beneficial effects in parkinson’s disease: In vitro evidence
Magistrelli, L., Amoruso, A., Mogna, L., Graziano, T., Cantello, R., Pane, M., & Comi, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00969 · Cited by 144
Capturing Ambulatory Activity Decline in Parkinson's Disease
Cavanaugh, J. T., Ellis, T. D., Earhart, G. M., Ford, M. P., Foreman, K. B., & Dibble, L. E. (2012) · Journal of Neurologic Physical Therapy · doi:10.1097/npt.0b013e318254ba7a · Cited by 141
Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease
Bolitho, S. J., Naismith, S. L., Rajaratnam, S. M. W., Grunstein, R. R., Hodges, J. R., Terpening, Z., Rogers, N., & Lewis, S. J. G. (2014) · Sleep Medicine · doi:10.1016/j.sleep.2013.10.016 · Cited by 139
Gut Metagenomics-Derived Genes as Potential Biomarkers of Parkinson’s Disease
Qian, Y., Yang, X., Xu, S., Huang, P., Li, B., Du, J., He, Y., Su, B., Xu, L.-M., Wang, L., et al. (2020) · Brain · doi:10.1093/brain/awaa201 · Cited by 139
Tractography patterns of subthalamic nucleus deep brain stimulation
Vanegas-Arroyave, N., Lauro, P. M., Huang, L., Hallett, M., Horovitz, S. G., Zaghloul, K. A., & Lungu, C. (2016) · Brain · doi:10.1093/brain/aww020 · Cited by 137
Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease
Schröder, J. B., Pawlowski, M., Meyer zu Hörste, G., Gross, C. C., Wiendl, H., Meuth, S. G., Ruck, T., & Warnecke, T. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.01081 · Cited by 134
The Impact of Type 2 Diabetes in Parkinson's Disease
Athauda, D., Evans, J., Wernick, A., Virdi, G., Choi, M. L., Lawton, M., Vijiaratnam, N., Girges, C., Ben‐Shlomo, Y., Ismail, K., et al. (2022) · Movement Disorders · doi:10.1002/mds.29122 · Cited by 132
Resting-state frontostriatal functional connectivity in Parkinson's disease-related apathy
Baggio, H. C., Segura, B., Garrido‐Millan, J. L., Marti, M., Compta, Y., Valldeoriola, F., Tolosa, E., & Junque, C. (2015) · Movement Disorders · doi:10.1002/mds.26137 · Cited by 131
A systematic review of impulse control disorders in Parkinson’s disease.
Callesen, M. B., Scheel-Krüger, J., Kringelbach, M. L., & Møller, A. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-120165 · Cited by 130
Structural correlates of facial emotion recognition deficits in Parkinson's disease patients
Baggio, H. C., Segura, B., Ibarretxe-Bilbao, N., Valldeoriola, F., Marti, M. J., Compta, Y., Tolosa, E., & Junqué, C. (2012) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2012.05.020 · Cited by 128
Clarke, C. E., Patel, S., Ives, N., Rick, C. E., Woolley, R., Wheatley, K., Walker, M. F., Zhu, S., Kandiyali, R., Yao, G., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20630 · Cited by 110
Self-citationShine, J. M., Muller, A. J., O’Callaghan, C., Hornberger, M., Halliday, G. M., & Lewis, S. J. (2015) · npj Parkinson's Disease · doi:10.1038/npjparkd.2015.3 · Cited by 106
Functional neurological disorders in Parkinson disease
Wissel, B. D., Dwivedi, A. K., Merola, A., Chin, D., Jacob, C., Duker, A. P., Vaughan, J. E., Lovera, L., LaFaver, K., Levy, A., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317378 · Cited by 106
Parkinson’s Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort
Lawton, M., Baig, F., Rolinski, M., Ruffman, C., Nithi, K., May, M. T., Ben-Shlomo, Y., & Hu, M. T. M. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140523 · Cited by 100
Christine, C. W., Richardson, R. M., Van Laar, A. D., Thompson, M. E., Fine, E. M., Khwaja, O. S., Li, C., Liang, G. S., Meier, A., Roberts, E. W., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000012952 · Cited by 89
Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies
Sarro, L., Senjem, M. L., Lundt, E. S., Przybelski, S. A., Lesnick, T. G., Graff-Radford, J., Boeve, B. F., Lowe, V. J., Ferman, T. J., Knopman, D. S., et al. (2016) · Brain · doi:10.1093/brain/aww193 · Cited by 89
Hurt, C. S., Burn, D. J., Hindle, J., Samuel, M., Wilson, K., & Brown, R. G. (2014) · British Journal of Health Psychology · doi:10.1111/bjhp.12043 · Cited by 80
Higher iron in the red nucleus marks Parkinson's dyskinesia
Lewis, M. M., Du, G., Kidacki, M., Patel, N., Shaffer, M. L., Mailman, R. B., & Huang, X. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.025 · Cited by 84
Vijiaratnam, N., Girges, C., Auld, G., Chau, M., Maclagan, K., King, A., Skene, S., Chowdhury, K., Hibbert, S., Morris, H., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047993 · Cited by 84
Cognitive determinants of dysarthria in Parkinson's disease: An automated machine learning approach
García, A. M., Arias‐Vergara, T., C. Vasquez‐Correa, J., Nöth, E., Schuster, M., Welch, A. E., Bocanegra, Y., Baena, A., & Orozco‐Arroyave, J. R. (2021) · Movement Disorders · doi:10.1002/mds.28751 · Cited by 77
Tong, Q., Zhang, L., Yuan, Y., Jiang, S., Zhang, R., Xu, Q., Ding, J., Li, D., Zhou, X., & Zhang, K. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.05.016 · Cited by 81
Parkinson's Disease Is Associated with Impaired Gut–Blood Barrier for Short‐Chain Fatty Acids
Yang, X., Ai, P., He, X., Mo, C., Zhang, Y., Xu, S., Lai, Y., Qian, Y., & Xiao, Q. (2022) · Movement Disorders · doi:10.1002/mds.29063 · Cited by 82
Increased Intestinal Permeability and Parkinson Disease Patients: Chicken or Egg?
Salat-Foix, D., Tran, K., Ranawaya, R., Meddings, J., & Suchowersky, O. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013202 · Cited by 80
Mindfulness for Motor and Nonmotor Dysfunctions in Parkinson’s Disease
Dissanayaka, N. N. W., Idu Jion, F., Pachana, N. A., O’Sullivan, J. D., Marsh, R., Byrne, G. J., & Harnett, P. (2016) · Parkinson's Disease · doi:10.1155/2016/7109052 · Cited by 79
Payne, T., Appleby, M., Buckley, E., van Gelder, L. M. A., Mullish, B. H., Sassani, M., Dunning, M. J., Hernandez, D., Scholz, S. W., McNeill, A., et al. (2023) · Movement Disorders · doi:10.1002/mds.29450 · Cited by 76
Gut Microbiota-Derived Metabolite Trimethylamine N-Oxide as a Biomarker in Early Parkinson’s Disease
Chung, S. J., Rim, J. H., Ji, D., Lee, S., Yoo, H. S., Jung, J. H., Baik, K., Choi, Y., Ye, B. S., Sohn, Y. H., et al. (2021) · Nutrition · doi:10.1016/j.nut.2020.111090 · Cited by 74
Synaptic proteins in CSF relate to Parkinson’s disease stage markers
Bereczki, E., Bogstedt, A., Höglund, K., Tsitsi, P., Brodin, L., Ballard, C., Svenningsson, P., & Aarsland, D. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-017-0008-2 · Cited by 72
Cognitive Behavioral Therapy for Anxiety in Parkinsonʼs Disease: A Randomized Controlled Trial
Moonen, A. J. H., Mulders, A. E. P., Defebvre, L., Duits, A., Flinois, B., Köhler, S., Kuijf, M. L., Leterme, A., Servant, D., de Vugt, M., et al. (2021) · Movement Disorders · doi:10.1002/mds.28533 · Cited by 71
Wu, G., Jiang, Z., Pu, Y., Chen, S., Wang, T., Wang, Y., Xu, X., Wang, S., Jin, M., Yao, Y., et al. (2022) · BMC Neurology · doi:10.1186/s12883-021-02544-7 · Cited by 67
Fanciulli, A., Strano, S., Ndayisaba, J. P., Goebel, G., Gioffrè, L., Rizzo, M., Colosimo, C., Caltagirone, C., Poewe, W., Wenning, G. K., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7339-2 · Cited by 67
Validation of differentially expressed brain‐enriched microRNAs in the plasma of PD patients
Ravanidis, S., Bougea, A., Papagiannakis, N., Koros, C., Simitsi, A. M., Pachi, I., Breza, M., Stefanis, L., & Doxakis, E. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51146 · Cited by 63
Ravanidis, S., Bougea, A., Karampatsi, D., Papagiannakis, N., Maniati, M., Stefanis, L., & Doxakis, E. (2021) · Movement Disorders · doi:10.1002/mds.28467 · Cited by 63
Akhtar, R. S., Licata, J. P., Luk, K. C., Shaw, L. M., Trojanowski, J. Q., & Lee, V. M. ‐. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14330 · Cited by 60
Lubomski, M., Xu, X., Holmes, A. J., Muller, S., Yang, J. Y. H., Davis, R. L., & Sue, C. M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.875261 · Cited by 59
Baschieri, F., Calandra-Buonaura, G., Doria, A., Mastrolilli, F., Palareti, A., Barletta, G., Solieri, L., Guaraldi, P., Martinelli, P., & Cortelli, P. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.02.011 · Cited by 55
Peripheral insulin and amylin levels in Parkinson's disease
Sánchez-Gómez, A., Alcarraz-Vizán, G., Fernández, M., Fernández-Santiago, R., Ezquerra, M., Cámara, A., Serrano, M., Novials, A., Muñoz, E., Valldeoriola, F., et al. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.08.018 · Cited by 44
Ravanidis, S., Bougea, A., Papagiannakis, N., Maniati, M., Koros, C., Simitsi, A., Bozi, M., Pachi, I., Stamelou, M., Paraskevas, G. P., et al. (2020) · Movement Disorders · doi:10.1002/mds.27928 · Cited by 51
Zhan, A., Little, M. A., Harris, D. A., Abiola, S. O., Dorsey, E. R., Saria, S., & Terzis, A. (2016) · arXiv · doi:10.48550/arxiv.1601.00960 · Cited by 50
Kong, K. H., Ng, H. L., Li, W., Ng, D. W., Tan, S. I., Tay, K. Y., Au, W. L., & Tan, L. C. S. (2018) · Brain and Behavior · doi:10.1002/brb3.897 · Cited by 48
Metadata
- Authors
- Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2010-11-10
- Volume
- 25
- Issue
- 15
- Pages
- 2649-2653
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2089085990
- Cited by
- 4,219
- References
- 53
- FWCI
- 8.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.